Sönmezer Murat, Oktay Kutluk
IVF Unit, Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey.
Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):514-22. doi: 10.1097/MED.0b013e32831a46fc.
This study aims to review the current state of different fertility preservation options in patients facing the risk of gonadal failure.
Various malignant and nonmalignant diseases have been successfully treated with high-dose chemotherapy or radiotherapy. Even though many young patients receiving these treatments are at risk of developing reproductive failure, a number of fertility preservation options ranging from embryo cryopreservation to ovarian tissue cryopreservation are now available.
Embryo cryopreservation is a well established technique to preserve fertility. The success rate with oocyte cryopreservation has been on the rise. Both oocyte and embryo freezing require ovarian stimulation and novel ovarian stimulation regimens utilizing aromatase inhibitors which have been developed for ovarian stimulation in women with estrogen sensitive cancer. Even though ovarian tissue cryopreservation is a novel technology, it is the only fertility preservation option for children and the only treatment strategy that can restore ovarian function. In-vitro maturation is a promising technology and can be applied in combination with ovarian tissue cryopreservation.
本研究旨在回顾面临性腺功能衰竭风险患者的不同生育力保存方法的现状。
多种恶性和非恶性疾病已通过高剂量化疗或放疗成功治疗。尽管许多接受这些治疗的年轻患者有发生生殖功能衰竭的风险，但现在有许多生育力保存方法可供选择，从胚胎冷冻保存到卵巢组织冷冻保存。
胚胎冷冻保存是一种成熟的生育力保存技术。卵母细胞冷冻保存的成功率一直在上升。卵母细胞和胚胎冷冻都需要卵巢刺激，并且已经开发出利用芳香化酶抑制剂的新型卵巢刺激方案，用于雌激素敏感癌症女性的卵巢刺激。尽管卵巢组织冷冻保存是一项新技术，但它是儿童唯一的生育力保存选择，也是唯一能够恢复卵巢功能的治疗策略。体外成熟是一项有前景的技术，可与卵巢组织冷冻保存联合应用。
